Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA approvals of Gilead’s Sovaldi (sofosbuvir) and Janssen/Medivir’s Olysio (simeprevir), followed by 2014 approvals of Gilead’s Harvoni (sofosbuvir/ledipasvir) and AbbVie’s Viekira Pak (paritaprevir/ombitasvir/ritonavir plus dasabuvir), ushered in the era of interferon (IFN)-free therapy for chronic HCV infections and have completely reshaped the HCV therapeutic market. With the availability of these new agents and the anticipated market entry of other promising emerging therapies in the near term, we expect the treatment landscape for HCV to continue to rapidly evolve with major improvements in drug safety and tolerability, efficacy, compliance, and treatment duration. This report focuses on current and anticipated use of all-oral HCV regimens , IFN-based regimens, and emerging IFN-free regimens by capturing patient market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior. For key brands, physician perceived strengths and weaknesses, barriers to uptake, and salesforce performance will be evaluated. Physician awareness, interest, and potential impact of agents in development are also gauged in this study.